Form 4: Inhibitor Therapeutics Director Ronald Osman Receives 50,000 Shares of Restricted Common Stock

Director Ronald Osman acquired 50,000 shares of restricted common stock in Inhibitor Therapeutics as compensation.

Summary

• Ronald E. Osman, a director and 10% owner of Inhibitor Therapeutics, Inc., acquired 50,000 shares of restricted common stock on April 1, 2025.
• The shares were issued as compensation under the company's 2014 Equity Incentive Plan.
• The price per share was $0.
• Following the transaction, Osman directly owns 100,000 shares and indirectly owns 23,554,985 shares through The Ronald E. Osman Trust III, for which he serves as the sole trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. There's no indication of positive or negative implications for the company's performance.

Positives

• The issuance of restricted stock aligns Osman's interests with those of the shareholders.
• The compensation is part of the company's 2014 Equity Incentive Plan, suggesting a structured approach to executive compensation.

Industry Context

This type of equity compensation is common in the biotech industry to attract and retain talent and align management interests with shareholders.

Stakeholder Impact

• The issuance of restricted stock could have a minor dilutive effect on existing shareholders.

Key Dates

Keywords

Inhibitor Therapeutics, Ronald Osman, restricted stock, Form 4, beneficial ownership, director compensation, equity incentive plan